Gregory Hamm
Director @AstraZeneca
Signup · Get unlimited contacts
WORK HISTORY
Director @AstraZeneca
Cambridge, GB
Drive strategic support for the Respiratory & Immunology (R&I) portfolio in Discovery Bioanalysis, collaborating with R&I leadership and communicating project impact in safety assessment and disease biology. • Develop and implement a global project tracking system in Airtable for 100+ scientists to optimize resource allocation, visualize KPIs, and enhance stakeholder engagement. • Establish an agile operating model to unite bioanalysis teams, streamline communication, and boost project efficiency.• Engage with senior leadership and stakeholders to influence global imaging strategies for efficacy and safety assessment.• Provide strategic guidance to project teams, acting as subject matter expert in imaging, leveraging spatial omics technologies to address key biological questions.• Lead matrix teams to deliver safety imaging strategies & metabolomics development aligned with company priorities and milestones.• Spearhead the integration of single-cell omics into early development pipelines through strategic external partnerships.• Initiate strategic partnerships between bioanalysis and imaging teams to streamline multi-omics processes.• Deliver several Tier 1 projects supporting regulatory interactions.• Foster external collaborations with institutions like Cambridge University, CRUK-CI to advance bioanalysis and spatial biology.
EDUCATION
Lycée Louis Vincent, Metz
Baccalauréat S, option physique-chimie
Universite de Lorraine
Master Recherche spécialité « Chimie physique moléculaire macromoléculaire et biomoléculaire », Chimie
Universite de Lorraine
PhD, Analytical Chemistry, Chemistry
ABOUT GREGORY HAMM
Dynamic and motivated director with 15 years of experience in drug discovery across both CRO and pharmaceutical sectors. Expertise in applying advanced omics technologies, including spatial metabolomics, proteomics, and transcriptomics, as well as digital pathology and in-vivo imaging, to drive drug development. Recognised as a KOL in Mass Spectrometry Imaging (MSI) with a strong scientific track record (h-index 22,~60 publications). Committed to pioneering imaging biomarker platforms for enhanced drug-target interaction prediction and decision-making.Strategic decision making Matrix team leadership Collaborative and innovative mindsetCoaching and mentorshipExpert knowledge in multi-omics/biomarker imaging platformsProject delivery & Management Business developmentPharmaceutical researchNew Drug modalitiesDisease biologyBioanalysis
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.